• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Chronic kidney disease is a general term for heterogeneous disorders affecting kidney
structure and function. The 2002 guidelines for definition and classification of this disease …

Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

The original KDIGO Clinical Practice Guideline for the Management of Blood Pressure in
Chronic Kidney Disease in the chronic kidney disease (CKD) population not receiving …

Background There is much uncertainty regarding the relative effects of angiotensin-
converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) in …

Accelerated cardiovascular disease is a frequent complication of renal disease. Chronic
kidney disease promotes hypertension and dyslipidemia, which in turn can contribute to the …

We consider a setting in which we have a treatment and a potentially large number of
covariates for a set of observations, and wish to model their relationship with an outcome of …

Coronary artery disease (CAD) is the single most common cause of death in the developed
world, responsible for about 1 in every 5 deaths. The morbidity, mortality, and …

Description: The American College of Physicians (ACP) developed this guideline to present
the evidence and provide clinical recommendations on the screening, monitoring, and …

Description: The Kidney Disease: Improving Global Outcomes (KDIGO) 2021 clinical
practice guideline for the management of blood pressure (BP) in patients with chronic kidney …